Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. For more information, please visit www.arvinas.com. We are seeking an experienced Director of Clinical Operations with deep expertise in neuroscience drug development to lead the global execution of early- and mid-stage clinical trials. This role will focus on Phase I/II (including Phase 1b) studies in neurodegenerative diseases, including Parkinson’s Disease (PD), atypical parkinsonism (e.g., PSP), SBMA, and related indications. This is a critical leadership role for a hands-on clinical operations expert with a proven track record in designing, operationalizing, and executing complex neuroscience trials. The ideal candidate brings deep experience overseeing CROs and external vendors, ensuring delivery of studies with operational excellence, high quality, and inspection readiness. The Director will be responsible for translating clinical development strategy into seamless, high-quality execution, from IND-enabling activities through early clinical development, ensuring studies are delivered on time, within budget, and in compliance with GCP, ICH guidelines, and company SOPs. This individual will also play a key role in building and scaling clinical operations infrastructure, processes, and teams to support a growing neuroscience pipeline. This position reports to the Executive Director, Clinical Operations and may be based remotely within the U.S.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
101-250 employees